Chai Discovery, an artificial intelligence drug discovery start-up, has raised $400 million in new funding that values the company at $3.8 billion. The substantial investment highlights growing investor confidence in using AI to accelerate pharmaceutical research and development.

The funding round underscores a broader trend of capital flowing into AI drug discovery platforms, as investors bet that machine learning can dramatically reduce the time and cost of identifying viable drug candidates. Traditional drug development typically takes over a decade and billions of dollars, with high failure rates.

Chai Discovery joins a competitive landscape of AI-focused biotech companies aiming to transform how new medicines are discovered. The company's valuation reflects expectations that its technology platform can deliver meaningful breakthroughs in targeting diseases that have proven resistant to conventional approaches.

This latest capital infusion will likely fuel expansion of Chai Discovery's computational capabilities, data infrastructure, and experimental validation programs as it advances its pipeline toward clinical development.